News

Filter

Current filters:

Parlodel

1 to 9 of 23 results

J&J To Cut 4,100 Jobs, Taking $800 Million Charge

08-12-1998

US health care major Johnson & Johnson has announced a restructuringplan that will lead to the loss of…

Bromocriptine MesylateCladribineDopamineDopamine HydrochlorideJohnson & JohnsonLeustatinNystatinOralParlodelRoche

Bromocriptine For Obesity

29-07-1998

Ergo Science has completed enrollment in its 300-patient Phase II studyof Ergoset (bromocriptine mesylate)…

Bromocriptine MesylateParlodel

Preclinical Data Provide Support For Ergoset

18-06-1998

Data from preclinical studies of Ergo Science's drug for type IIdiabetes, Ergoset (bromocriptine mesylate),…

Bromocriptine MesylateParlodel

J&J Hooks Up With Ergo For Bromocriptine

25-02-1998

Ergo Science has licensed worldwide rights to its oral dopamine agonistfor non-insulin-dependent diabetes,…

Bromocriptine MesylateDopamineDopamine HydrochlorideHumulin 70-30Humulin NHumulin RInsulinJohnson & JohnsonNystatinOralParlodel

French Reimbursable Delistings

18-12-1997

Deletions of pharmaceutical products from France's official reimbursablespecialties list, made under…

AstemizoleBromocriptine MesylateHismanalJanssen-CilagParlodelSandoz

Sandoz To License Orion Parkinson's Drug

04-03-1996

Sandoz has licensed worldwide rights to a Parkinson's disease drug developed by Orion Pharma of Finland,…

Bromocriptine MesylateCarbidopaCarbidopa-LevodopaComtanDoparEldeprylEntacaponeLevodopaLodosynMerck KGaAOrion PharmaParlodelRocheSandozSelegiline HclSinemet

1 to 9 of 23 results

COMPANY SPOTLIGHT

Menarini

Back to top